biostudies-literatureUnknown390Liu BC<h4>Objective</h4>To evaluate the efficacy and safety of anrikefon (formerly known as HSK21542), a novel selective peripherally restricted kappa opioid receptor agonist, in patients with chronic kidney disease associated pruritus.<h4>Design</h4>Multicentre, double blind, randomised placebo controlled phase 3 trial.<h4>Setting</h4>50 centres in China, June 2022 to June 2024.<h4>Participants</h4>652 patients with moderate to severe CKD associated pruritus undergoing haemodialysis were screened: 545 were randomly assigned (1:1 ratio) to receive either anrikefon (n=275) or placebo (n=270).<h4>Interventions</h4>Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks, followed by an optional open label extension phase with anrikefon treatment for 40 weeks.<h4>MaiBMJ (Clinical research ed.)e085208https://www.ebi.ac.uk/biostudies/studies/S-EPMC12362199biostudies-literatureEfficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.PMC12362199Sun FYLi HBWu LHuang JWang CLXu YZWan QJWang XHGuo QZhang PWang LLi GSWang XLWang XPChen WXie DQWang YGao BHYao LWang DGZhang XZLi YLZhang DLBai YLLi YMiu LYLin HLChen WLXu YAnrikefon-302 study collaborator groupLiu HRen WLong GMao NDu STLiu BCLiu LChen BMLiao BLi ZLChen JHWei YZhou LHZhou HJiang HLZhou LWang JXZhong AMYan RGuan TJLi FQLv LYi XMLuo PYan TKfalseEfficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.<h4>Objective</h4>To evaluate the efficacy and safety of anrikefon (formerly known as HSK21542), a novel selective peripherally restricted kappa opioid receptor agonist, in patients with chronic kidney disease associated pruritus.<h4>Design</h4>Multicentre, double blind, randomised placebo controlled phase 3 trial.<h4>Setting</h4>50 centres in China, June 2022 to June 2024.<h4>Participants</h4>652 patients with moderate to severe CKD associated pruritus undergoing haemodialysis were screened: 545 were randomly assigned (1:1 ratio) to receive either anrikefon (n=275) or placebo (n=270).<h4>Interventions</h4>Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks, followed by an optional open label extension phase with anrikefon treatment for 40 weeks.<h4>Mai2025-01-01T00:00:00Z2025 Aug2026-05-29T15:04:18.453Z2026-04-08T05:11:37.658ZS-EPMC123621994082989610.1136/bmj-2025-085208